|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Abed, J, Emgård, JEM, Zamir, G, Faroja, M, Almogy, G, Grenov, A, Sol, A, Naor, R, Pikarsky, E, Atlan, KA, Mellul, A, Chaushu, S, Manson, AL, Earl, AM, Ou, N, Brennan, CA, Garrett, WS, Bachrach, G|
|Journal||Cell Host Microbe|
|Date Published||2016 Aug 10|
Fusobacterium nucleatum is associated with colorectal cancer and promotes colonic tumor formation in preclinical models. However, fusobacteria are core members of the human oral microbiome and less prevalent in the healthy gut, raising questions about how fusobacteria localize to CRC. We identify a host polysaccharide and fusobacterial lectin that explicates fusobacteria abundance in CRC. Gal-GalNAc, which is overexpressed in CRC, is recognized by fusobacterial Fap2, which functions as a Gal-GalNAc lectin. F. nucleatum binding to clinical adenocarcinomas correlates with Gal-GalNAc expression and is reduced upon O-glycanase treatment. Clinical fusobacteria strains naturally lacking Fap2 or inactivated Fap2 mutants show reduced binding to Gal-GalNAc-expressing CRC cells and established CRCs in mice. Additionally, intravenously injected F. nucleatum localizes to mouse tumor tissues in a Fap2-dependent manner, suggesting that fusobacteria use a hematogenous route to reach colon adenocarcinomas. Thus, targeting F. nucleatum Fap2 or host epithelial Gal-GalNAc may reduce fusobacteria potentiation of CRC.
|Alternate Journal||Cell Host Microbe|
|Grant List||U19 AI110818 / AI / NIAID NIH HHS / United States|